Acumen Pharmaceuticals (ABOS) Corporate presentation summary

Strategy and market

• Focus is early Alzheimer's disease, targeting toxic amyloid beta oligomers with sabirnetug and developing next-generation antibodies using Enhanced Brain Delivery (EBD).

• An estimated 7.2 million Americans aged 65 and older live with Alzheimer's; the population is projected to reach 13.8 million by 2060.

• Treatment opportunities include improving efficacy, reducing ARIA-E risk, offering more convenient delivery, targeting earlier amyloid, and expanding into preclinical AD.

Sabirnetug clinical program

• Sabirnetug is a monoclonal antibody selective for toxic amyloid beta oligomers; Phase 1 results were positive, and the program has FDA Fast Track designation for early AD.

• ALTITUDE-AD completed enrollment of 542 participants in March 2025; Phase 2 topline results are expected in November 2026, with change in iADRS as the primary endpoint.

• Phase 1 showed dose-related target engagement, with saturation between 25 and 60 mg/kg; biomarker changes after three doses indicated downstream pharmacology.

• Phase 1 reported five ARIA-E cases, approximately 10%; none occurred among six ApoE4 homozygotes, and no deaths or study-drug-related serious adverse events were reported.

• A Phase 1 healthy-volunteer study of subcutaneous sabirnetug showed systemic exposure supporting further development; a dosing option is being developed with Halozyme's ENHANZE technology.

Enhanced Brain Delivery program

• EBD combines an oligomer-targeted antibody with a transferrin-receptor brain carrier; the JCR Pharmaceuticals agreement includes an exclusive option to license and develop up to two candidates.

• In mouse studies, EBD fusion proteins showed 32–55x higher cumulative brain exposure than ACU193 in wild-type mice and 63–68x higher exposure than ACU193 or ACU234 in an AD mouse model.

• In non-human primates, EBD candidates achieved 14–40x higher brain levels than native antibodies 24 hours after dosing; no changes in red blood cell count, hematocrit, hemoglobin or reticulocyte count were observed after subcutaneous dosing.

• EBD preclinical candidate data were announced in early 2026; lead clinical candidate IND filing is targeted for mid-2027.